Latest Market Entry News

Sparc Technologies has unveiled SparcESTM, a graphene additive range designed for electrostatic and conductive coatings, aiming to disrupt a $1.65 billion market driven by data centres, semiconductors, and EV battery manufacturing.

Clarity Pharmaceuticals will present compelling data at EANM 2026 demonstrating its 64Cu-SAR-bisPSMA imaging agent’s superior detection of prostate cancer recurrence and promising therapeutic results from 67Cu-SAR-bisPSMA in advanced disease.

TruScreen Group has completed a substantially oversubscribed NZ$2.9 million rights issue, boosting total capital raised to over NZ$4 million. The funds are set to support the company’s global expansion in cervical screening technology.

Tāiko Critical Minerals has locked in a key 304-hectare land parcel for its Barrytown project with an $18 million conditional purchase, clearing a major hurdle towards mining and production targets.

BCAL Diagnostics has developed BREASTEST Monitor, a blood test showing promising accuracy in detecting local breast cancer recurrence in women over 50, aiming to simplify post-treatment monitoring.

Aguia Resources has rapidly converted its Pampafós phosphate fertiliser project into commercial sales, securing AUD 600,000 in revenue within 14 days, anchored by a 2,000-tonne contract with a leading Brazilian agricultural cooperative.

Harvest Technology Group has transitioned from assessing to actively executing its international defence market strategy by engaging a US national security advisory firm and appointing Dr Oleksandra Molloy as Defence Strategic Advisor for Europe.

SciDev Ltd has completed a strategic review addressing past underperformance and is refocusing on an integrated water solutions platform targeting core markets. The company confirmed FY26 guidance with revenue of $82 to $87 million and underlying EBITDA of approximately $4 million, while maintaining a sound balance sheet.

TruScreen has secured clinical validation from the world’s largest cervical screening study in China, setting the stage for rapid market expansion across Asia, Africa, and Europe.

Imricor Medical Systems has submitted the third of four Premarket Approval modules to the FDA, marking a key step towards US approval of its MR-guided cardiac ablation devices.

OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.

LTR Pharma has secured a binding US telehealth commercialisation framework for its intranasal erectile dysfunction treatment ROXUS, committing to at least 150,000 prescriptions in the first year and granting exclusivity to Shed Holdings' platform.